ArticleMovement disorders clinical practice2026
Prevalence and Associations of Abnormal Levels of Vitamin B6 in People with Parkinson's Disease.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIn people with Parkinson's disease, abnormal levels of vitamin B6 may be associated with polyneuropathy and epileptic seizures, including medication-refractory status epilepticus.
objectivesTo estimate the prevalence and explore associations of abnormal levels of vitamin B6 in people with Parkinson's disease.
methodsIn this cross-sectional study, fasting serum levels of vitamin B6 and related metabolites were measured in 144 people with Parkinson's disease randomly recruited from eligible clinic patients, compared with 144 historical controls matched for age, sex, diet, and vitamin supplementation. Mixed-effects logistic regression was used to compare the prevalences of abnormal B6 levels, and mixed-effects analysis of variance was used to compare mean B6 levels between groups. Mixed effects regression models were used to examine associations between B6 levels and pre-defined demographic and clinical variables.
resultsMean age was 71 years (range = 43-87) and 38.2% were female. Almost all were treated with carbidopa/levodopa (n = 140/144, mean levodopa dosage = 800 mg/day, mean treatment duration = 78 months). The prevalence of B6 deficiency in people with Parkinson's disease was 36.1% compared to 4.9% in controls (OR = 11.4, 95% CI = 4.9-26.5, p < 0.001). The average B6 level in people with Parkinson's disease was approximately half of that in controls (ratio of geometric means = 0.49, 95% CI = 0.41-0.58, p < 0.001). The severity of levodopa-associated motor complications (p = 0.04) and the presence of epileptic seizures (p = 0.006) were associated with lower log-transformed B6 levels.
conclusionsVitamin B6 deficiency is highly prevalent in people with Parkinson's disease. Active monitoring should be conducted in those with levodopa-associated motor complications or epileptic seizures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.